•  
  •  
 

Author Credentials

Sydney Graham, MPH Emily Sloane, M.D. Nadim Bou Zgheib, M.D.

DOI

10.33470/2379-9536.1326

Abstract

Since gaining FDA approval in 2014, pembrolizumab, a PD-1 immune checkpoint inhibitor, has been utilized in the management of cancers that progress following first-line therapy.While the pathological response to pembrolizumab is favorable, immune related adverse events (irAEs) can be elicited and require prompt diagnosis and management based on grading and severity, which can include discontinuation of immunotherapy.Our case concerns a 66-year-old female with recurrent endometrial cancer who was treated with pembrolizumab, and developed inflammatory arthritis following therapy. We provide a succinct review of the pathogenesis and risk factors associated with irAEs, as well as diagnosis and management strategies.

Conflict(s) of Interest

Sydney Graham, Emily Sloane, and Nadim Bou Zgheib have no conflicts oof interest to disclose.

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Share

COinS